Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | NPC1 | O15118 | 8/20 | 0.57 |
| ▸ | RAB9A | P51151 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 5/20 | 0.56 |
| ▸ | SNCA | P37840 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 6/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 6/20 | 0.52 |
| ▸ | GLA | P06280 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24426106 | 0.91 | NPC1 (0.58) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL4446655 | 0.85 | MAPT (0.63) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL9868410 | 0.77 | MAPT (0.62) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL5777616 | 0.74 | MAPT (0.76) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL2628262 | 0.73 | APP (1.00) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL178156 | 0.73 | APP (1.00) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL12422217 | 0.72 | MAPT (0.81) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL7531819 | 0.72 | MAPT (0.72) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL7531824 | 0.71 | MAPT (0.71) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL13853341 | 0.71 | APP (0.94) | MAPTKDM4ENPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2022011091-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | PSMG3, HSPA5, TTR | MAPT 204/4885KDM4E 4067/4885NPC1 964/4885 |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | MAPT 3768/4885KDM4E 2203/4885NPC1 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.